荣昌生物制药（烟台）股份有限公司

Home
About Us
RemeGen Co., Ltd. (Yantai) was co-founded in 2008 by Mr. Wang Weidong, founder of Rongchang Pharmaceuticals, and Dr. Jianmin Fang a Canadian-American scientist. RemeGen is headquartered in Yantai, Shandong Province, China, with R&D centers and offices in China and the United States.

■Our Company ■Our Vision ■Board of Directors ■Management Team
Products/R&D Pipelines
Telitacicept

The World’s First Innovative Dual-Target Biological Medication to Treat Systemic Lupus Erythematosus

Disitamab Vedotin

The First Independently Developed Novel ADC Drug in China

■Marketed Products ■Marketing Team ■Product Pipeline
Science&Manufacturing
■Innovation Capacity ■Technology Platform ■Manufacturing ■Quality System ■Talent Team
Investors

STAR Market stock code：荣昌生物：688331.SH

【2024.05.07】 Monthly Returns Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024

HKEX stock code 荣昌生物：09995.HK

【2024.04.26】 [Overseas Regulatory Announcement - Other] An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

■Financial Reports ■Circulars ■Activities and Presentations

■Investor Events Calendar ■Corporate Governance ■Investor Relation Contact Information
News
- Company News
- Media Reports
ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma

BERLIN, Oct. 20, 2025 /PRNewswire/ -- At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally adv

■Company News ■Media Reports
Join Us
■Recruitment ■Working at RemeGen ■Compensation and Benefits
Contact Us
■Yantai, China

Address: No. 58 Beijing Middle Road, Yantai Development Zone, Shandong, China.

Telephone:（+86）535-3573511

■Company Address ■Clinical Trial ■Human Resource ■ Adverse Reactions Reporting

Products/R&D Pipelines

Telitacicept

Trade name: Tai’ai ®Other Name: RC18

RC18

Telitacicept is a first-in-class fusion protein independently developed by RemeGen, which targets both recombinant B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) .It is characterized by a rapid onset of action, a high response rate, and a managable safety profile.

Drug Instruction

Demonstrated promissing efficacy in multiple indications

Treatment of systemic lupus erythematosus

High response rate

SRI4 response rate was 82.6% at Week 52

Rapid onset of action

From Week 4 the response rate was higher in telitacicept group than that in placebo group

Improvement in system involvement

Significant improvement in mucocutaneous involvement,musculoskeletal involvement,immunologic involvement,and hematologic involvement

Reduction in proteinuria

Significant reduction in proteinuria at Week 24 and 48

Increase in complement levels

Complement levels of C3 and C4,important bioactive proteins of the complement system,increased significantly since Week 4 and continued to increase until Week 52

Treatment of Rheumatoid arthritis

High response rate

Significant improvement in ACR20 response rate from Week 4,with ACR20 response rate of 67.4% at Week 24 and 72.2% at Week 48

Significantly delayed joint structural damage

92.8% of participants had no radiographic progression at Week 24 and 89.9% at Week 48

In addition,telitacicept can significantly improve the inflammatory level and physical function of participants and relieve pain; the proportion of participants reaching the treatment endpoint (DAS28-ESR ≤ 3.2) continued to increase until Week 48

Treatment of Myasthenia gravis

Significantly decreaseed MG-ADL and QMG scores

At Week 24,the MG-ADL score decreased by 5.74 points from baseline,and the proportion of participantts with a ≥3-point improvement in MG-ADL scores was 98.1%,which was much higher than that in placebo group.

QMG score decreased by 8.66 points from baseline,and the proportion of participantts with a ≥5-point improvement in QMG scores was 87%,which was much higher than that in placebo group

Continuous improvement

MG-ADL and QMG scores continued to decrease over time in the telitacicept group,with peak improvement at Week 24

Explore the treatment of B cell-mediated immune diseases

In March 2021, the new drug marketing application of telitacicept for the treatment of systemic lupus erythematosus (SLE) passed the priority review and approval process. As an urgently needed clinical drug with outstanding clinical value, it was conditionally approved for marketing in China and entered the National Reimbursement Drug List (NRDL). In November 2023, telitacicept was formally granted full approval from conditional approval by NMPA. In July 2024, telitacicept was approved for marketing for the treatment of rheumatoid arthritis (RA). In May 2025, telitacicept was approved for marketing for the treatment of myasthenia gravis (MG).

Myasthenia Gravis
Rheumatoid Arthritis
Lupus Nephritis
Systemic Lupus Erythematosus
Membranous Nephritis
Sjogren's syndrome
IgA Nephritis
...

To inquire about medication details or report side effects, please reach out through:

4001110266 Available Monday to Friday, 8:30 AM to 5:00 PM (excluding public holidays)

remegenpv@remegen.com